Biosensors based on nanomaterials are becoming a research hotspot for the rapid detection of pathogenic bacteria. Herein, a “turn-on” fluorescent biosensor based on a FRET system was constructed for the...

No abstract

The long noncoding RNA myocardial infarction associated transcript (MIAT) played a critical role in lung cancer. Present study aimed to measure serum MIAT levels and investigate its clinical value in lung cancer. Serum was collected from 109 lung cancer and 61 healthy controls, and MIAT levels were measured using RT-qPCR and compared. The relations between serum MIAT and the clinical characteristics of cancer were explored. Diagnostic power of MIAT for lung cancer was analyzed by plotting an ROC curve. Serum MIAT levels were significantly higher in lung cancer than in healthy controls (t = 3.288, P < 0.01). Serum MIAT levels were increased significantly in patients at middle-late stages than in those at early stages(t = 2.862, P < 0.01), and significantly higher in patients with lymph node metastasis than in those without (t = 4.112, P < 0.01). The cut-off value of serum MIAT for the diagnosis of lung cancer was 0.945, with a sensitivity of 66.1%, specificity of 63.9%, and area under the curve of 0.65 (95% confidence interval, 0.57–0.73). Serum MIAT levels were increased significantly among lung cancer and related to TNM stage or lymph node metastasis, suggesting the potential of MIAT as a marker of lung cancer.

No abstract